We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01025128
First Posted: December 3, 2009
Last Update Posted: July 21, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Metzger Muriel, Clalit Health Services
  Purpose
Because of its high sun exposure, Israel was traditionally supposed to be protected from vitamin D deficiency, and the country food products hardly contain vitamin D supplements. However the Jerusalem ultra-Orthodox population, which constitutes a significant fraction of the city population, is at risk of developing vitamin D deficiency due to low sun exposure, as consequence of its dressing code covering most of the body and very limited time of outside activities. The investigators aim is to check whether vitamin D deficiency is found more frequently in the ultra-Orthodox male population in comparison to a non-ultra-Orthodox male population, and to study its eventual consequences. Correlation between vitamin D levels and PTH levels will be examined, according to age and to creatinine levels. Bone mineral density (BMD) will be evaluated in 2 selected subgroups of subjects (with lowest and highest vitamin D levels), and re-evaluated after 6 months of vitamin D supplementation in vitamin D-deficient subjects. An increase in BMD within 6 months would suggest osteomalacia as the main cause of low BMD in these subjects.

Condition Intervention Phase
Vitamin D Deficiency Secondary Hyperparathyroidism Osteomalacia Drug: 25 OH vitamin D Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Screening

Resource links provided by NLM:


Further study details as provided by Metzger Muriel, Clalit Health Services:

Primary Outcome Measures:
  • plasma vitamin D level [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • bone mineral density before vitamin D supplementation [ Time Frame: 8 months ]
  • plasma PTH level [ Time Frame: 6 months ]
  • bone mineral density after vitamin D supplementation in vitamin D deficient subjects [ Time Frame: 13 months ]

Enrollment: 210
Study Start Date: January 2010
Study Completion Date: July 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: group A low D
ultra-Orthodox clinics patients aged 18-39 with lowest vitamin D levels
Drug: 25 OH vitamin D
oral supplementation of 25 OH vitamin D at dose of 2000 units/d for 3 months then 1000 units/d for 3 months
No Intervention: group A high D
ultra-Orthodox clinics patients aged 18-39 with highest vitamin D levels
Active Comparator: group B low D
mixed population clinics patients aged 18-39 with lowest vitamin D levels
Drug: 25 OH vitamin D
oral supplementation of 25 OH vitamin D at dose of 2000 units/d for 3 months then 1000 units/d for 3 months
No Intervention: group B high D
mixed population clinics patients aged 18-39 with highest vitamin D levels

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male subjects aged 18-70
  • If age below 40 must not be under any chronic medication

Exclusion Criteria:

  • Medication: anti-convulsivants, non-topical steroids (past or present), anti-rejection medications
  • Malabsorptive diseases (Crohn's disease, cystic fibrosis,Whipple' disease, s/p bariatric surgery)
  • Morbid obesity (BMI above 35)
  • Rheumatoid arthritis
  • Liver failure
  • Nephrotic syndrome
  • Chronic kidney disease
  • Genetic disorder
  • Malignancy
  • Primary hyperparathyroidism
  • Granulomatous disease
  • Hyperthyroidism
  • Nephrolithiasis (present or past)
  • S/P skin grafts surgery
  • Mental disorder or cognitive disorder
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01025128


Locations
Israel
Endocrinology Clinic, Clalit Health Services
Jerusalem., Israel
Sponsors and Collaborators
Clalit Health Services
Investigators
Principal Investigator: Muriel Metzger, MD Clalit Health Services, Jerusalem, Israel
Principal Investigator: Anat Tsur, MD Clalit Health Services, Jerusalem, Israel
  More Information

Responsible Party: Metzger Muriel, MD, Clalit Health Services
ClinicalTrials.gov Identifier: NCT01025128     History of Changes
Other Study ID Numbers: K129/09
First Submitted: December 1, 2009
First Posted: December 3, 2009
Last Update Posted: July 21, 2014
Last Verified: July 2014

Additional relevant MeSH terms:
Hyperparathyroidism
Vitamin D Deficiency
Hyperparathyroidism, Secondary
Osteomalacia
Parathyroid Diseases
Endocrine System Diseases
Avitaminosis
Deficiency Diseases
Malnutrition
Nutrition Disorders
Rickets
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Calcium Metabolism Disorders
Metabolic Diseases
Vitamins
Vitamin D
Ergocalciferols
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents


To Top